Cargando…

A Novel Insight Into Fecal Occult Blood Test for the Management of Gastric Cancer: Complication, Survival, and Chemotherapy Benefit After R0 Resection

BACKGROUND: Previous studies have shown that the all-cause mortality and non-colorectal cancer mortality of patients with fecal occult blood test (FOBT) positivity are significantly increased, implying that FOBT results may have more prognostic value. METHODS: Retrospective analysis was performed fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Xu, Binbin, Xu, Yu, Wu, Yuan, Xie, Jianwei, Wang, Jiabin, Lin, Jianxian, Chen, Qiyue, Cao, Longlong, Zheng, Chaohui, Huang, Changming, Li, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905191/
https://www.ncbi.nlm.nih.gov/pubmed/33643891
http://dx.doi.org/10.3389/fonc.2020.526746
_version_ 1783655062746169344
author Lu, Jun
Xu, Binbin
Xu, Yu
Wu, Yuan
Xie, Jianwei
Wang, Jiabin
Lin, Jianxian
Chen, Qiyue
Cao, Longlong
Zheng, Chaohui
Huang, Changming
Li, Ping
author_facet Lu, Jun
Xu, Binbin
Xu, Yu
Wu, Yuan
Xie, Jianwei
Wang, Jiabin
Lin, Jianxian
Chen, Qiyue
Cao, Longlong
Zheng, Chaohui
Huang, Changming
Li, Ping
author_sort Lu, Jun
collection PubMed
description BACKGROUND: Previous studies have shown that the all-cause mortality and non-colorectal cancer mortality of patients with fecal occult blood test (FOBT) positivity are significantly increased, implying that FOBT results may have more prognostic value. METHODS: Retrospective analysis was performed for gastric cancer (GC) patients who underwent R0 gastrectomy from July 2007 to July 2014 at our hospital. Propensity score matching (PSM) was used to reduce confounding bias and a computerized technique for the nearest available score matching without replacement was applied. The cumulative survival rate was calculated using the Kaplan-Meier method and a log-rank test. Cox proportional hazards regression and logistic regression was used to determine the independent prognostic factors associated with survival and postoperative complications, respectively. The expression level of tumor-associated macrophages (TAMs) and proinflammatory cytokines (TNF-α, IL-6) were evaluated by immunohistochemical (IHC). RESULTS: A total of 3,003 patients were included and 246 patients (8.2%) were in preoperative FOBT positive status. There was no significant difference in demographic data between preoperative FOBT positive and negative group after a 1:4 PSM. The overall postoperative complications, major complications, and anastomotic leakage were significantly higher in the preoperative FOBT-positive group than in the preoperative FOBT-negative group. Moreover, preoperative FOBT-positivity was an independent risk factor for 5-year overall survival (OS) (HR: 1.32, p = 0.005). For stage II/III patients, the postoperative adjuvant chemotherapy (PAC) benefit was found in preoperative FOBT-negative group (5-year OS: 49.9 vs. 36.8%, p = 0.001), whereas the PAC benefit was lost in preoperative FOBT-positive groups (5-year OS: 40.8 vs. 37.7% p = 0.896). Finally, IHC found that preoperative FOBT-positivity in patients was significantly associated with higher TAMs infiltration and higher expression of IL-6 and TNF-α in tumor tissues than in the preoperative FOBT-negative group. CONCLUSION: As a simple and low-cost method, preoperative FOBT results can predict both complications and survival after R0 gastrectomy for GC. More importantly, stage II/III GC patients with FOBT-positive seem not benefit from PAC alone. Further exploration is warranted.
format Online
Article
Text
id pubmed-7905191
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79051912021-02-26 A Novel Insight Into Fecal Occult Blood Test for the Management of Gastric Cancer: Complication, Survival, and Chemotherapy Benefit After R0 Resection Lu, Jun Xu, Binbin Xu, Yu Wu, Yuan Xie, Jianwei Wang, Jiabin Lin, Jianxian Chen, Qiyue Cao, Longlong Zheng, Chaohui Huang, Changming Li, Ping Front Oncol Oncology BACKGROUND: Previous studies have shown that the all-cause mortality and non-colorectal cancer mortality of patients with fecal occult blood test (FOBT) positivity are significantly increased, implying that FOBT results may have more prognostic value. METHODS: Retrospective analysis was performed for gastric cancer (GC) patients who underwent R0 gastrectomy from July 2007 to July 2014 at our hospital. Propensity score matching (PSM) was used to reduce confounding bias and a computerized technique for the nearest available score matching without replacement was applied. The cumulative survival rate was calculated using the Kaplan-Meier method and a log-rank test. Cox proportional hazards regression and logistic regression was used to determine the independent prognostic factors associated with survival and postoperative complications, respectively. The expression level of tumor-associated macrophages (TAMs) and proinflammatory cytokines (TNF-α, IL-6) were evaluated by immunohistochemical (IHC). RESULTS: A total of 3,003 patients were included and 246 patients (8.2%) were in preoperative FOBT positive status. There was no significant difference in demographic data between preoperative FOBT positive and negative group after a 1:4 PSM. The overall postoperative complications, major complications, and anastomotic leakage were significantly higher in the preoperative FOBT-positive group than in the preoperative FOBT-negative group. Moreover, preoperative FOBT-positivity was an independent risk factor for 5-year overall survival (OS) (HR: 1.32, p = 0.005). For stage II/III patients, the postoperative adjuvant chemotherapy (PAC) benefit was found in preoperative FOBT-negative group (5-year OS: 49.9 vs. 36.8%, p = 0.001), whereas the PAC benefit was lost in preoperative FOBT-positive groups (5-year OS: 40.8 vs. 37.7% p = 0.896). Finally, IHC found that preoperative FOBT-positivity in patients was significantly associated with higher TAMs infiltration and higher expression of IL-6 and TNF-α in tumor tissues than in the preoperative FOBT-negative group. CONCLUSION: As a simple and low-cost method, preoperative FOBT results can predict both complications and survival after R0 gastrectomy for GC. More importantly, stage II/III GC patients with FOBT-positive seem not benefit from PAC alone. Further exploration is warranted. Frontiers Media S.A. 2021-02-11 /pmc/articles/PMC7905191/ /pubmed/33643891 http://dx.doi.org/10.3389/fonc.2020.526746 Text en Copyright © 2021 Lu, Xu, Xu, Wu, Xie, Wang, Lin, Chen, Cao, Zheng, Huang and Li http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lu, Jun
Xu, Binbin
Xu, Yu
Wu, Yuan
Xie, Jianwei
Wang, Jiabin
Lin, Jianxian
Chen, Qiyue
Cao, Longlong
Zheng, Chaohui
Huang, Changming
Li, Ping
A Novel Insight Into Fecal Occult Blood Test for the Management of Gastric Cancer: Complication, Survival, and Chemotherapy Benefit After R0 Resection
title A Novel Insight Into Fecal Occult Blood Test for the Management of Gastric Cancer: Complication, Survival, and Chemotherapy Benefit After R0 Resection
title_full A Novel Insight Into Fecal Occult Blood Test for the Management of Gastric Cancer: Complication, Survival, and Chemotherapy Benefit After R0 Resection
title_fullStr A Novel Insight Into Fecal Occult Blood Test for the Management of Gastric Cancer: Complication, Survival, and Chemotherapy Benefit After R0 Resection
title_full_unstemmed A Novel Insight Into Fecal Occult Blood Test for the Management of Gastric Cancer: Complication, Survival, and Chemotherapy Benefit After R0 Resection
title_short A Novel Insight Into Fecal Occult Blood Test for the Management of Gastric Cancer: Complication, Survival, and Chemotherapy Benefit After R0 Resection
title_sort novel insight into fecal occult blood test for the management of gastric cancer: complication, survival, and chemotherapy benefit after r0 resection
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905191/
https://www.ncbi.nlm.nih.gov/pubmed/33643891
http://dx.doi.org/10.3389/fonc.2020.526746
work_keys_str_mv AT lujun anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT xubinbin anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT xuyu anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT wuyuan anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT xiejianwei anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT wangjiabin anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT linjianxian anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT chenqiyue anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT caolonglong anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT zhengchaohui anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT huangchangming anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT liping anovelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT lujun novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT xubinbin novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT xuyu novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT wuyuan novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT xiejianwei novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT wangjiabin novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT linjianxian novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT chenqiyue novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT caolonglong novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT zhengchaohui novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT huangchangming novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection
AT liping novelinsightintofecaloccultbloodtestforthemanagementofgastriccancercomplicationsurvivalandchemotherapybenefitafterr0resection